Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

Nyxoah NYXH recently received FDA approval for its Genio system, an innovative therapy for moderate to severe Obstructive Sleep Apnea (OSA). Featuring a leadless, battery-free design powered by an ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

“AI can be used as a gym – a place for training, challenge, and growth – or as a diet pill, a way to bypass effort in the ...

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...

The system is compatible with 1.5T and 3T magnetic resonance imaging scans and eliminates the need for an implanted battery.

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).

The Food and Drug Administration (FDA) has approved the Genio ® system for the treatment of patients with moderate to severe obstructive sleep apnea (OSA) with an apnea-hypopnea index (AHI) of ...